We`re Polar Thermal


Polar Thermal Packaging Ltd manufacture a range of temperature control insulated systems. They include transport packaging for blood products, food, vaccines, pharmaceuticals, fine chemicals and many other specialist applications. Our entry in to the thermal control market came following a request by the Ministry of Defence to solve the problem of frozen food melting at the dockside. Since then our CEO Paul Harrison and the team, have put their design skills and entrepreneurial flair to good use, making applications for the National Blood Service, Van den Berg Oils, DHL, Excel Global Logistics, Marks and Spencer, Tesco’s, Sainsbury’s, Astra Zeneca and Pfizer to name but a few.

Our primary target markets are Pharmaceutical, Clinical Research Organisations, Health Service Providers, Perishable Food Distributors and Logistics Companies, although our range of unique products are easily transferable to many other industries and service sectors.

We believe we have the best performing British product in its field, and all our products are manufactured at our Wiltshire based factory. All systems are reusable and have a two year guarantee.


Our products are now used throughout the world – we are continually exploring new markets and seeking partners that share our vision. If this is you then please get in touch!


In recent testing by NHS England our products scored 100/100 – our closest competitor scored 72. Why? Because whilst many products may be made to look like ours they do not use the same materials nor do they have our British workmanship


Our products have been deployed in the harshest and most testing environments and proved themselves – whether it is constant daily use in UK hospitals or in conflict-zones like Afghanistan you can be assured of effective and durable service.

Front Office

Paul Harrison

Paul Harrison

Chief Executive

Paul is the founder and leader of Polar Thermal - he has built a reputation as a problem solver with a 'can do' attitude. Paul has an old-school view on integrity and values getting the job done.

Alex Porter

Alex Porter

Commercial Director

Alex is an experienced manager tasked with driving the business forward as it continues to grow.

Jemma Griffiths

Jemma Griffiths

Office Manager

Jemma runs the office with a firm hand, keeps the staff and the books in order. If you want anything done Jemma is the person to start with.

"Perfection is achieved, not when there is nothing more to add, but when there is nothing left to take away."


Who's Counting?

UK Clients
Projects Delivered
NHS Score




At our world class manufacturing facility in Warminster, UK we produce nearly all of our products using state-of-the-art equipment operated by highly skilled, time-served staff. It is not our policy to contract out, and we stand over everything that we supply.



We provide a full design service as well as designing and developing our own products.

Test Facility

Test Facility

We have full in-house testing facilities up to 6 metres x 3 metres - temperatures from -40°C to +40°C.

From the Blog

Polar delivers again in Covid 19 Convalescent Plasma Trial

Today another 100 Blood Plasma Systems were finished by the team in the Warminster factory. Extra shifts were put on over the Bank Holiday to keep ahead of schedule.

Whilst Oxford Univesity is leading the way the US Food & Drug Administration (FDA) has issued guidance for trials of the process.

Already accepted in China the use of antibody-rich plasma has reportedly been very beneficial for many patients.

In the UK, thousands of recovered Covid-19 patients have volunteered to give plasma for the trials, and the collection and transport using Polar Thermal Blood Plasma Systems is being scaled up.

It is important to understand that this is not being put forward as a vaccine or cure, but there is significant hope that it may reduce the symptoms and slow down the effect of the virus.

Polar Thermal Vaccine Bags

Landmark partnership announced for development of COVID-19 vaccine

The University of Oxford has today announced an agreement with the UK-based global biopharmaceutical company AstraZeneca for the further development, large-scale manufacture and potential distribution of the COVID-19 vaccine candidate currently being trialled by the University.

Polar Thermal Vaccine Transport Systems are used by both the University of Oxford and AstraZeneca, indeed Polar Thermal has been involved in one of the largest clinical trials of its kind. The company is scaling up and adjusting production schedules to support the initiative in any way that it can. Stock levels on most systems are good with a holding of the 600 Vaccine Shipper being made available for immediate delivery along with the 10, 20 and 30 litre systems in use daily with the NHS.

The partnership is to begin immediately with the final terms being agreed in the coming weeks.  This will allow for rapid vaccination around the world if the COVID-19 vaccine candidate proves to be effective. The vaccine candidate was developed by the University’s Jenner Institute who began trials in humans last week jointly with the University’s Oxford Vaccine Group.

It is the first such partnership to be formed since the Government launched its dedicated Vaccines Taskforce to help find, test and deliver a new coronavirus vaccine just two weeks ago.  It also comes alongside £20 million Government funding for Oxford University’s vaccine research and support for the institution’s clinical trials. 

Under the new agreement, as well as providing UK access as early as possible if the vaccine candidate is successful, AstraZeneca will work with global partners on the international distribution of the vaccine, particularly working to make it available and accessible for low and medium income countries.

Both partners have agreed to operate on a not-for-profit basis for the duration of the coronavirus pandemic, with only the costs of production and distribution being covered. Oxford University and its spin-out company Vaccitech, who jointly have the rights to the platform technology used to develop the vaccine candidate, will receive no royalties from the vaccine during the pandemic. Any royalties the University subsequently receives from the vaccine will be reinvested directly back into medical research, including a new Pandemic Preparedness and Vaccine Research Centre. The centre is being developed in collaboration with AstraZeneca.

Professor Sir John Bell, Regius Professor of Medicine at Oxford University, said: “Our partnership with AstraZeneca will be a major force in the struggle against pandemics for many years to come. We believe that together we will be in a strong position to start immunising against coronavirus once we have an effective approved vaccine. Sadly, the risk of new pandemics will always be with us and the new research centre will enhance the world’s preparedness and our speed of reaction the next time we face such a challenge.”

The Vice-Chancellor of Oxford University, Professor Louise Richardson said: “Like my colleagues all across Oxford, I am deeply proud of the work of our extraordinarily talented team of academics in the Jenner Institute and the Oxford Vaccine Group. They represent the best tradition of research, teaching and contributing to the world around us, that has been the driving mission of the University of Oxford for centuries. Like people all across the country, we are wishing them success in developing an effective vaccine. If they are successful, our partnership with Astra Zeneca will ensure that the British people and people across the world, especially in low and middle income countries, will be protected from this terrible virus as quickly as possible.”

Business Secretary Alok Sharma said: “This collaboration between Oxford University and AstraZeneca is a vital step that could help rapidly advance the manufacture of a coronavirus vaccine. It will also ensure that should the vaccine being developed by Oxford University’s Jenner Institute work, it will be available as early as possible, helping to protect thousands of lives from this disease.”

Health Secretary Matt Hancock said: “Across government, we are working night and day to stop the spread of coronavirus and protect our NHS. But in the long run, a vaccine remains our best hope of defeating this virus for good. So I am determined to do everything in my power to develop an effective vaccine and get it to the people of the UK as soon as possible. I want the UK to lead the world in developing a coronavirus vaccine – and I will back our scientists to the hilt in doing so.”

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “As COVID-19 continues its grip on the world, the need for a vaccine to defeat the virus is urgent. This collaboration brings together University of Oxford’s world-class expertise in vaccinology and AstraZeneca’s global development, manufacturing and distribution capabilities. Our hope is that, by joining forces, we can accelerate the globalisation of a vaccine to combat the virus and protect people from the deadliest pandemic in a generation.” 

Bill Enright, CEO of Vaccitech, said: “We are delighted to facilitate this extensive collaboration in support of the development of the vaccine candidate in order to make it available as quickly as possible.  We believe this vaccine candidate provides significant validation for our ChAdOx platform, which is one of the few to have already induced neutralising antibodies against coronavirus spike proteins in human studies for MERS. We are committed to doing all we can to support our scientific founders at the Jenner Institute in order to overcome this unprecedented global crisis.”

Polar Thermal and the NHS

The Polar Thermal factory is open and making vital systems for the NHS – priority at the moment is Blood Bags for Platelets and Plasma (see next story), but it was very rewarding to see our Red Blood Bags feature in Peter Kay’s rework of the Road to Amarillo on BBC One:

Peter Kay supports the NHS

We are adapting to the new normal – it certainly isn’t easy, but everyone in the company has stepped forward to make it happen – and it is great to know that all our Research and Development has been of benefit to the NHS.

COVID-19 and 5-Day Shipper

Testing times for everyone, but some developments may prove helpful in this crisis. Polar Thermal developed a system for Pfizer for large-scale deployment of vaccines in a pan-European clinical trial – a hand-portable system to carry 600 vaccines and maintain them safely within temperature range for 5 days, and the lightweight pallet-based solution called Bluekoat which was used to distribute 1,200 vaccines.

Field-tested and used in anger these two systems performed superbly and received an unprecedented endorsement from the Pfizer director responsible. (copy available!)

Polar is operating safely currently but ensuring that vital orders for the NHS and our cold-chain logistics customers are fulfilled. Phones are being answered, office staff are working remotely wherever possible and key factory staff have embraced the safe working practice laid out by Public Health England.

To that end we have 80 complete 5-Day Shippers available for immediate dispatch and a good stock of all Vaccine Bags for supply to the NHS.

NHS Vaccine Bags ready for dispatch

We are committed to working through the crisis – we are collaborating well with our fulfillment partners and suppliers and hope to continue an uninterrupted service.

For more information on the 5 Day Shippers – CLICK HERE

Give Blood – we look after it!

One customer we are particularly proud to have is NHS Blood & Transplant – this summer we celebrate 5 years as the supplier of Whole Blood Transport Systems to the NHS. As part of that comprehensive framework agreement we regularly service the systems at our Warminster factory,

We are all rightly proud of our NHS – a major British institution that leads the world, and at Polar Thermal we would like to think that we are doing our bit – another, albeit minor, British institution!

The rigorous testing process we went through to achieve our position with the NHS was demanding, as it should be. Independent inspections of our factory, work processes, warranties and materials – the final result 100/100 against all comers. The company and their system that came closest to us achieved a score of 72/100 – we were especially pleased that on this occasion our British engineering should come out significantly ahead of our German competitor!

That said, the NHS endorsement validates our Whole Blood, Platelet, Plasma and Transplant Systems for use by the other 27 European Blood Alliance members as well as the National Blood Services from Australia, Canada and New Zealand.

Polar Thermal is working with the Department for International Trade to explore these opportunities.

Thermal Roll Cage

Polar Thermal has been working with one of their key customers for several years on a new solution for the safe and efficient delivery of chilled and frozen food to multiple drop-offs.

All the theory in the world may get you some great ideas, but there is nothing like the day-to-day reality of making it happen to push you to a solution that ticks all the boxes. The Performance Roll Cage is sturdy, yet lightweight – it has well-positioned handles for moving the cage around and securing it quickly in the delivery vehicle. Strong wheels with quick-release brakes make the cage manoeuvrable and steady. The waterproof cover protects the contents in all conditions.

Inside the thermal cover is a sliding thermal pillow which drops down as product is taken out ensuring the chill space is maintained (cold chain people will know that empty space is what we definitely don’t need!), and the sleeved coolant mesh-packs do their job, whilst reducing condensation impact on the boxed product.

Add to that constant temperature monitoring, recording and reporting and you have the complete Cold Chain Delivery Solution.

Polar Thermal is focusing more and more on the last mile – some even more exciting announcements are just around the corner.



Get in touch!

Contact Info